Avalo Therapeutics, Inc.
No SEC Form 4 filings for $AVTX in the last 30 days.
See all $AVTX insider activity →AbbVie's phase III data for lutikizumab in hidradenitis suppurativa caused Avalo Therapeutics' shares to fall 39% to $7.45 on Oct. 22. AbbVie's study showed positive results in 1,400 patients with moderate to severe HS.
H.C. Wainwright reiterated a Buy rating and $30.00 price target for Avalo Therapeutics (NASDAQ:AVTX), which is trading near its 52-week low. The firm expects positive Phase 3 results from AbbVie's INTREPID study by mid-November or December 2026. Avalo has a strong balance sheet and upcoming FDA milestones in 2026-2027. Cantor Fitzgerald also reiterated an Overweight rating, citing IL-1 inhibition's potential. Three analysts recently raised earnings estimates.
Avalo Therapeutics (AVTX) granted a director 1,352 stock options at $15.33 per share, exercisable from 2026 and expiring in 2036. The options are tied to 1,352 shares of common stock.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AVTX (Avalo Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent AVTX coverage spans earnings, financial news and corporate actions.
Sharp downside pressure on Avalo as investors reassess its competitive position.
Analyst reiteration may support modest upside expectations but no immediate catalyst.
Director option grant may signal confidence but limited market impact.
Phase III entry could unlock significant upside if data confirm efficacy, supporting a higher valuation.
Insider sell may signal CFO's lack of confidence, potentially pressuring the stock short term.
AlphAI scores every news story that mentions AVTX with an AI model for sentiment and relevance, and aggregates insider trades from Avalo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AbbVie's phase III data for lutikizumab in hidradenitis suppurativa caused Avalo Therapeutics' shares to fall 39% to $7.45 on Oct. 22. AbbVie's study showed positive results in 1,400 patients with moderate to severe HS.
1 min readH.C. Wainwright reiterated a Buy rating and $30.00 price target for Avalo Therapeutics (NASDAQ:AVTX), which is trading near its 52-week low. The firm expects positive Phase 3 results from AbbVie's INTREPID study by mid-November or December 2026. Avalo has a strong balance sheet and upcoming FDA milestones in 2026-2027. Cantor Fitzgerald also reiterated an Overweight rating, citing IL-1 inhibition's potential. Three analysts recently raised earnings estimates.
1 min readAvalo Therapeutics (AVTX) granted a director 1,352 stock options at $15.33 per share, exercisable from 2026 and expiring in 2036. The options are tied to 1,352 shares of common stock.
1 min readAvalo Therapeutics (AVTX) is advancing its anti-IL-1 beta antibody, abdakibart, to phase III trials for hidradenitis suppurativa (HS) after positive phase II results. The company plans to expand indications in dermatology and rheumatology, develop a long-acting version, and secure financial support. The strategy includes differentiated dosing and device approaches.
1 min readSullivan Christopher Ryan (Chief Financial Officer) sold 72,725 shares of Avalo Therapeutics, Inc. (AVTX) at an average of $19.94 ($19.85–$20.05, $1.45M total) across 3 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.
1 min readAvalo Therapeutics (Nasdaq: AVTX) reported Q2 2026 net loss of $36.4 million, or $0.83 per share, with no reported product revenue. Operating expenses rose to $31.5 million. Cash, cash equivalents and investments were $472.2 million as of June 30, 2026, and an equity offering generated about $405.0 million net proceeds. Shares closed $18.70 on Aug. 6.
5 min readAvalo Therapeutics (Nasdaq: AVTX) reported Q2 2026 results and business updates. The company plans to start a registrational Phase 3 for abdakibart in hidradenitis suppurativa in H1 2027 and expects to submit an IND for AVTX-010 in H1 2027. Cash, cash equivalents and investments were $472.2M at June 30, 2026, funding operations into 2029. Q2 net loss was $36.4M.
6 min readAvalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates • Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027 • Expanded pipeline with AVTX-010, a lon
6 min readAvalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. avtx-20260623 0001534120 false 0001534120 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readAvalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-3.1 2 ex-31certificateofdesignat.htm EX-3.1 Document Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES C-1 NON-VOTING CONVERTIBLE PREFERRED STOCK OF AVALO THERAPEUTICS, INC. Pursuant to Section 151 of the Delaware General Corporation Law Avalo Therapeutics, Inc., a Delaware cor
6 min read
